Phase 1 trial in 80 healthy adults without HIV-1: three broadly neutralising antibodies (PGDM1400LS, VRC07-523LS, PGT121.414.LS) given IV or subcutaneously were safe, with no serious adverse events, estimated half-lives of 44-65 days and no antagonistic interactions.
RCTn = 80
Mahomed et al. Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, VRC07-523LS, and PGT121.414.LS infused intravenously or subcutaneously (HVTN 140/HPTN 101 part B): a phase 1, randomised trial